Morgan Stanley
EGRX

Morgan Stanley’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Morgan Stanley’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-192,213
Closed -$717K – 8232
2024
Q3 		$717K Sell
192,213
-108,235
-36% -$516K ﹤0.01% 5230
2024
Q2 		$1.68M Sell
300,448
-74,881
-20% -$326K ﹤0.01% 4670
2024
Q1 		$1.97M Sell
375,329
-218,399
-37% -$1.2M ﹤0.01% 4588
2023
Q4 		$3.11M Buy
593,728
+429,653
+262% +$4.24M ﹤0.01% 4685
2023
Q3 		$2.59M Sell
164,075
-17,970
-10% -$323K ﹤0.01% 4224
2023
Q2 		$3.54M Sell
182,045
-63,765
-26% -$1.51M ﹤0.01% 4019
2023
Q1 		$6.97M Sell
245,810
-4,468
-2% -$133K ﹤0.01% 3484
2022
Q4 		$7.32M Buy
250,278
+18,287
+8% +$581K ﹤0.01% 3389
2022
Q3 		$6.13M Buy
231,991
+19,682
+9% +$722K ﹤0.01% 3497
2022
Q2 		$9.43M Buy
212,309
+65,014
+44% +$2.99M ﹤0.01% 3121
2022
Q1 		$7.29M Buy
147,295
+14,909
+11% +$716K ﹤0.01% 3275
2021
Q4 		$6.74M Sell
132,386
-16,311
-11% -$845K ﹤0.01% 3402
2021
Q3 		$8.29M Sell
148,697
-19,229
-11% -$946K ﹤0.01% 3110
2021
Q2 		$7.19M Buy
167,926
+12,193
+8% +$503K ﹤0.01% 3385
2021
Q1 		$6.5M Sell
155,733
-28,192
-15% -$1.31M ﹤0.01% 3136
2020
Q4 		$8.56M Buy
183,925
+17,096
+10% +$800K ﹤0.01% 2679
2020
Q3 		$7.09M Buy
166,829
+115,747
+227% +$5.06M ﹤0.01% 2361
2020
Q2 		$2.45M Buy
51,082
+1,773
+4% +$88.5K ﹤0.01% 3399
2020
Q1 		$2.27M Sell
49,309
-21,473
-30% -$1.08M ﹤0.01% 3252
2019
Q4 		$4.25M Sell
70,782
-25,065
-26% -$1.49M ﹤0.01% 3371
2019
Q3 		$5.42M Sell
95,847
-46,409
-33% -$2.61M ﹤0.01% 2789
2019
Q2 		$7.92M Buy
142,256
+68,937
+94% +$3.6M ﹤0.01% 2415
2019
Q1 		$3.7M Sell
73,319
-16,225
-18% -$722K ﹤0.01% 3007
2018
Q4 		$3.61M Sell
89,544
-16,166
-15% -$833K ﹤0.01% 3257
2018
Q3 		$7.33M Sell
105,710
-61,246
-37% -$4.64M ﹤0.01% 2752
2018
Q2 		$12.6M Buy
166,956
+23,741
+17% +$1.49M ﹤0.01% 2108
2018
Q1 		$7.55M Sell
143,215
-23,642
-14% -$1.37M ﹤0.01% 2622
2017
Q4 		$8.91M Sell
166,857
-24,054
-13% -$1.34M ﹤0.01% 2516
2017
Q3 		$11.4M Sell
190,911
-99,518
-34% -$6.02M ﹤0.01% 2157
2017
Q2 		$22.9M Buy
290,429
+162,015
+126% +$13.2M 0.01% 1410
2017
Q1 		$10.7M Sell
128,414
-43,769
-25% -$3.25M ﹤0.01% 2134
2016
Q4 		$13.7M Sell
172,183
-120,256
-41% -$8.74M ﹤0.01% 1916
2016
Q3 		$20.5M Sell
292,439
-422,714
-59% -$23.4M 0.01% 1434
2016
Q2 		$27.7M Buy
715,153
+691,423
+2,914% +$28.8M 0.01% 1166
2016
Q1 		$961K Sell
23,730
-23,793
-50% -$1.51M ﹤0.01% 3971
2015
Q4 		$4.21M Buy
47,523
+31,273
+192% +$2.47M ﹤0.01% 2832
2015
Q3 		$1.2M Sell
16,250
-7,928
-33% -$660K ﹤0.01% 3962
2015
Q2 		$1.96M Sell
24,178
-172,365
-88% -$11.2M ﹤0.01% 3653
2015
Q1 		$8.23M Buy
196,543
+190,963
+3,422% +$5.42M ﹤0.01% 2270
2014
Q4 		$86K Buy
5,580
+397
+8% +$5.07K ﹤0.01% 5611
2014
Q3 		$65K Buy
5,183
+4,378
+544% +$54.3K ﹤0.01% 5638
2014
Q2 		$12K Sell
805
-21,993
-96% -$251K ﹤0.01% 6151
2014
Q1 		$291K Buy
+22,798
New +$309K ﹤0.01% 4906

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Morgan Stanley's EGRX Position: Q4 2024 in Review

Morgan Stanley sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 192,213 shares — an estimated $717K sold.

Morgan Stanley first reported a position in EGRX in Q1 2014 and held it in 43 quarters. The position peaked at $27.7M in Q2 2016. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Morgan Stanley reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Morgan Stanley sold 192,213 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $717K.
  • Morgan Stanley first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 43 quarters.
  • Morgan Stanley's Eagle Pharmaceuticals, Inc. position peaked at $27.7M in Q2 2016.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.